SCHEMBL1445829

SCHEMBL1445829

[2H][C@](N)(CCC)C(O)C(=O)NC1CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 1/20 0.41
METAP1 P53582 1/20 0.39
LMNA P02545 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
SIGMAR1 Q99720 1/20 0.35
MME P08473 2/20 0.34
GPR88 Q9GZN0 1/20 0.34
METAP2 P50579 3/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
EPHX1 P07099 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1464146 1.00 SMYD3 (0.41) SMYD3METAP1LMNABLMKMT2A
SCHEMBL1445966 1.00 SMYD3 (0.41) SMYD3METAP1LMNABLMKMT2A
Hydrochloric Acid SCHEMBL1464088 0.98 SMYD3 (0.40) SMYD3METAP1LMNABLMKMT2A
Hydrochloric Acid SCHEMBL1445815 0.98 SMYD3 (0.40) SMYD3METAP1LMNABLMKMT2A
SCHEMBL3045972 0.83 SMYD3 (0.43) SMYD3METAP1LMNABLMKMT2A
SCHEMBL13058644 0.83 SMYD3 (0.43) SMYD3METAP1LMNABLMKMT2A
SCHEMBL328991 0.83 SMYD3 (0.43) SMYD3METAP1LMNABLMKMT2A
SCHEMBL329193 0.83 SMYD3 (0.43) SMYD3METAP1LMNABLMKMT2A
SCHEMBL329101 0.83 SMYD3 (0.43) SMYD3METAP1LMNABLMKMT2A
SCHEMBL2331995 0.83 SMYD3 (0.43) SMYD3METAP1LMNABLMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247532-B2 Deuterated hepatitis C protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-21 US disclosed
US-20110071074-A1 DEUTERATED HEPATITIS C PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-24 US disclosed
EP-2295401-A2 Deuterated hepatitis C protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-16 EP disclosed
EP-2194039-A1 Process for preparing optically enriched compounds Vertex Pharmceuticals Incorporated (US) 2010-06-09 EP disclosed
EP-1993994-A2 DEUTERATED HEPATITIS C PROTEASE INHIBITORS Vertex Pharmceuticals Incorporated (US) 2008-11-26 EP disclosed
WO-2007109080-A2 DEUTERATED HEPATITIS C PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-09-27 WO disclosed
US-20070225297-A1 Deuterated hepatitis C protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2007-09-27 US disclosed
US-20070225297-A1 Deuterated hepatitis C protease inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225297-A1 Deuterated hepatitis C protease inhibitors PEPD, CTRL, CTSC SMYD3 3675/4885METAP1 190/4885LMNA 2067/4885
US-20110071074-A1 DEUTERATED HEPATITIS C PROTEASE INHIBITORS PEPD, CTRL, CTSC SMYD3 3675/4885METAP1 190/4885LMNA 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.